Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Redefining Rectal Cancer Priorities Through a Watch-and-Wait Paradigm: Balancing Cancer Cure and Quality of Life.

Felder SI, Hoffe SE.

J Oncol Pract. 2019 Mar;15(3):135-136. doi: 10.1200/JOP.19.00083. No abstract available.

PMID:
30861366
2.

Recognition of Tumor Invasion of a Pancreatic Head Biliary Stent During Stereotactic Body Radiation Therapy.

Song E, Segarra D, Latifi K, Leuthold S, Belinc D, Pena L, Malafa MP, Frakes JM, Hoffe SE.

Pract Radiat Oncol. 2019 Jan 29. pii: S1879-8500(19)30009-8. doi: 10.1016/j.prro.2019.01.008. [Epub ahead of print] No abstract available.

PMID:
30708132
3.

Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.

Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, Fontaine J, Pimiento JM, Hoffe SE.

Dis Esophagus. 2018 Dec 31. doi: 10.1093/dote/doy124. [Epub ahead of print]

PMID:
30597022
4.

Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma.

Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Hoffe S.

J Gastrointest Oncol. 2018 Oct;9(5):840-846. doi: 10.21037/jgo.2018.05.14.

5.

Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.

Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, Tsimafeyeu I, Thomas CR Jr, Tjulandin S, Likhacheva A.

J Cancer Educ. 2018 Nov 22. doi: 10.1007/s13187-018-1447-0. [Epub ahead of print]

PMID:
30467774
6.

Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.

Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B.

J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. doi: 10.1016/j.jvir.2018.04.001. Epub 2018 Jul 2.

PMID:
30042074
7.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
8.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
9.

Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization.

Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE.

J Gastrointest Oncol. 2018 Jun;9(3):546-552. doi: 10.21037/jgo.2018.03.04.

10.

Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail.

Jin WH, Hoffe SE, Shridhar R, Strom T, Venkat P, Springett GM, Hodul PJ, Pimiento JM, Meredith KL, Malafa MP, Frakes JM.

J Gastrointest Oncol. 2018 Jun;9(3):487-494. doi: 10.21037/jgo.2018.02.02.

11.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
12.

Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.

Jin WH, Mellon EA, Frakes JM, Murimwa GZ, Hodul PJ, Pimiento JM, Malafa MP, Hoffe SE.

J Gastrointest Oncol. 2018 Feb;9(1):24-34. doi: 10.21037/jgo.2017.09.13.

13.

Kinetic analysis of contralateral liver hypertrophy after radioembolization of primary and metastatic liver tumors.

Orcutt ST, Abuodeh Y, Naghavi A, Frakes J, Hoffe S, Kis B, Anaya DA.

Surgery. 2018 May;163(5):1020-1027. doi: 10.1016/j.surg.2017.11.020. Epub 2018 Jan 8.

PMID:
29325784
14.

Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?

Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP.

World J Gastroenterol. 2017 Dec 14;23(46):8193-8199. doi: 10.3748/wjg.v23.i46.8193.

15.

CT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma.

Saeed N, Shridhar R, Almhanna K, Hoffe S, Chuong M, Meredith K.

J Gastrointest Oncol. 2017 Oct;8(5):833-841. doi: 10.21037/jgo.2017.07.03.

16.

Adjuvant chemotherapy and outcomes in esophageal carcinoma.

Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K.

J Gastrointest Oncol. 2017 Oct;8(5):816-824. doi: 10.21037/jgo.2017.07.10.

17.

Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery.

Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, Pimiento JM, Fontaine JP, Hoffe SE, Frakes JM.

J Gastrointest Oncol. 2017 Oct;8(5):808-815. doi: 10.21037/jgo.2017.06.11.

18.

Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy.

Frakes J, Mellon EA, Springett GM, Hodul P, Malafa MP, Fulp WJ, Zhao X, Hoffe SE, Shridhar R, Meredith KL.

J Gastrointest Oncol. 2017 Oct;8(5):758-765. doi: 10.21037/jgo.2017.08.05.

19.

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Venkat PS, Hoffe SE, Frakes JM.

Cancer Control. 2017 Jul-Sep;24(3):1073274817729259. doi: 10.1177/1073274817729259. Review.

20.

Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.

Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP.

Cancer Control. 2017 Oct-Dec;24(5):1073274817729076. doi: 10.1177/1073274817729076.

21.

Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.

Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM.

J Surg Oncol. 2018 Feb;117(2):150-159. doi: 10.1002/jso.24808. Epub 2017 Aug 22.

PMID:
28833197
22.

Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer.

Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K.

Endosc Int Open. 2017 Jun;5(6):E496-E504. doi: 10.1055/s-0043-104861. Epub 2017 May 31.

23.

Superficial and peripheral dose in compensator-based FFF beam IMRT.

Zhang DG, Feygelman V, Moros EG, Latifi K, Hoffe S, Frakes J, Zhang GG.

J Appl Clin Med Phys. 2017 Jan;18(1):151-156. doi: 10.1002/acm2.12018. Epub 2016 Dec 21.

24.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2017 Mar;15(3):370-398.

PMID:
28275037
25.

Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.

Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G.

World J Gastroenterol. 2016 Dec 21;22(47):10406-10414. doi: 10.3748/wjg.v22.i47.10406.

26.

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.

Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R.

J Vasc Interv Radiol. 2017 Feb;28(2):254-259. doi: 10.1016/j.jvir.2016.09.025. Epub 2016 Dec 7.

PMID:
27955832
27.

Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.

Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE.

Acta Oncol. 2017 Mar;56(3):391-397. doi: 10.1080/0284186X.2016.1256497. Epub 2016 Nov 25.

PMID:
27885876
28.

Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms.

Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M; Florida Pancreas Collaborative.

Oncotarget. 2016 Dec 27;7(52):85785-85797. doi: 10.18632/oncotarget.11768.

29.

Outcomes in patients with brain metastasis from esophageal carcinoma.

Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K.

J Gastrointest Oncol. 2016 Aug;7(4):562-9. doi: 10.21037/jgo.2016.03.12.

30.

Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.

Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R.

J Gastrointest Oncol. 2016 Aug;7(4):547-55. doi: 10.21037/jgo.2016.03.15.

31.

Hepatic radioembolization from transradial access: initial experience and comparison to transfemoral access.

Kis B, Mills M, Hoffe SE.

Diagn Interv Radiol. 2016 Sep-Oct;22(5):444-9. doi: 10.5152/dir.2016.15571.

32.

Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy.

Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1399-1404. doi: 10.1016/j.ijrobp.2016.03.050. Epub 2016 Apr 8.

PMID:
27319288
33.

Small caliber covered self-expanding metal stents in the management of malignant dysphagia.

Kucera S, Barthel J, Klapman J, Shridhar R, Hoffe S, Harris C, Almhanna K, Meredith K.

J Gastrointest Oncol. 2016 Jun;7(3):411-9. doi: 10.21037/jgo.2015.12.03.

34.

Determining the optimal number of lymph nodes harvested during esophagectomy.

Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K.

J Gastrointest Oncol. 2016 Jun;7(3):387-94. doi: 10.21037/jgo.2015.12.02.

35.

Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center.

Salem AI, Thau MR, Strom TJ, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL.

Dis Esophagus. 2017 Jan 1;30(1):1-7. doi: 10.1111/dote.12484.

PMID:
27149640
36.

Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA.

J Gastrointest Oncol. 2016 Apr;7(2):221-7. doi: 10.3978/j.issn.2078-6891.2015.075.

37.

Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy.

Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL.

J Gastrointest Oncol. 2016 Apr;7(2):206-12. doi: 10.3978/j.issn.2078-6891.2015.104.

38.

AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy.

Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL.

J Gastrointest Oncol. 2016 Apr;7(2):158-65. doi: 10.3978/j.issn.2078-6891.2015.067.

39.

Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility.

Dhadham GC, Hoffe S, Harris CL, Klapman JB.

Endosc Int Open. 2016 Mar;4(3):E378-82. doi: 10.1055/s-0042-100720. Epub 2016 Mar 3.

40.

Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method.

Goodman KA, Patton CE, Fisher GA, Hoffe SE, Haddock MG, Parikh PJ, Kim J, Baxter NN, Czito BG, Hong TS, Herman JM, Crane CH, Hoffman KE.

Pract Radiat Oncol. 2016 May-Jun;6(3):166-175. doi: 10.1016/j.prro.2015.11.014. Epub 2015 Nov 24.

PMID:
26922700
41.

Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.

Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D.

Radiother Oncol. 2016 Feb;118(2):382-6. doi: 10.1016/j.radonc.2016.01.018. Epub 2016 Feb 6.

PMID:
26861740
42.

Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis.

Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A.

Am J Clin Oncol. 2018 Mar;41(3):236-241. doi: 10.1097/COC.0000000000000261.

PMID:
26796313
43.

Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer.

Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K.

Am J Clin Oncol. 2018 Mar;41(3):254-258. doi: 10.1097/COC.0000000000000258.

PMID:
26703814
44.

Palliative Care in Older Patients With Cancer.

Balducci L, Dolan D, Hoffe SA.

Cancer Control. 2015 Oct;22(4):480-8. Review.

PMID:
26678975
45.

Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.

Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP.

Ann Surg Oncol. 2016 Apr;23(4):1371-9. doi: 10.1245/s10434-015-5006-1. Epub 2015 Dec 10.

PMID:
26661409
46.

Investigational drugs for treating anal cancer and future perspectives.

Bustamante L, Frakes J, Hoffe S, Kim R.

Expert Opin Investig Drugs. 2016;25(1):51-62. doi: 10.1517/13543784.2016.1116518. Epub 2015 Dec 11. Review.

PMID:
26560877
47.

Outcomes of resected pancreatic cancer in patients age ≥70.

Hayman TJ, Strom T, Springett GM, Balducci L, Hoffe SE, Meredith KL, Hodul P, Malafa M, Shridhar R.

J Gastrointest Oncol. 2015 Oct;6(5):498-504. doi: 10.3978/j.issn.2078-6891.2015.038.

48.

Management of borderline resectable pancreatic cancer.

Mahipal A, Frakes J, Hoffe S, Kim R.

World J Gastrointest Oncol. 2015 Oct 15;7(10):241-9. doi: 10.4251/wjgo.v7.i10.241. Review.

49.

The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.

Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM.

J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.

PMID:
26394724
50.

Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.

Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R.

Radiother Oncol. 2015 Oct;117(1):159-64. doi: 10.1016/j.radonc.2015.07.018. Epub 2015 Jul 30.

PMID:
26235848

Supplemental Content

Loading ...
Support Center